Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A large B-cell lymphoma located in the body cavities, characterized by pleural, peritoneal, and pericardial fluid lymphomatous effusions and that is always associated with human herpes virus-8 (HHV-8).
Biomarker and diagnostic research for primary effusion lymphoma has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
10 clinical trials registered, 2 recruiting. Interventions under study include drug therapy, other interventions, biologic therapy, and procedural interventions. Pipeline includes 1 PHASE2, 6 PHASE1, 1 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT00006518](https://clinicaltrials.gov/study/NCT00006518) |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 4:23 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer |
— |
National Cancer Institute (NCI) |
RECRUITING |
[NCT05544019](https://clinicaltrials.gov/study/NCT05544019) | Study of SGR-1505 in Mature B-Cell Neoplasms | PHASE1 | Schrödinger, Inc. | RECRUITING |
129 publications have been identified in PubMed for primary effusion lymphoma. Research spans Basic Science / Preclinical (37%), Review / Meta-Analysis (27%), and Case Report / Case Series (20%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 48 | 37% |
Research summaries | 35 | 27% |
Patient case studies | 26 | 20% |
Disease patterns and progression | 8 | 6% |
New treatment approaches | 7 | 5% |
Testing and diagnosis research | 3 | 2% |
Other research | 2 | 2% |
Mwazha A (2026). [PMID: 42099060](https://pubmed.ncbi.nlm.nih.gov/42099060/). *Int J Surg Pathol*. [Diagnostic / Biomarker]
McMahon S (2026). [PMID: 41993451](https://pubmed.ncbi.nlm.nih.gov/41993451/). *bioRxiv*. [Basic Science / Preclinical]
Zhou D (2026). [PMID: 41659624](https://pubmed.ncbi.nlm.nih.gov/41659624/). *bioRxiv*. [Gene Therapy / Novel Therapeutics]
Das N (2026). [PMID: 41713257](https://pubmed.ncbi.nlm.nih.gov/41713257/). *Virology*. [Basic Science / Preclinical]
Roberts K (2026). [PMID: 42225084](https://pubmed.ncbi.nlm.nih.gov/42225084/). *Cancer Rep (Hoboken)*. [Case Report / Case Series]
Vaughn JL (2026). [PMID: 41510578](https://pubmed.ncbi.nlm.nih.gov/41510578/). *Hematological oncology*. [Epidemiology / Natural History]
Maeda K (2026). [PMID: 42081990](https://pubmed.ncbi.nlm.nih.gov/42081990/). *Eur J Pharmacol*. [Gene Therapy / Novel Therapeutics]
Bhattacharya S (2026). [PMID: 42146703](https://pubmed.ncbi.nlm.nih.gov/42146703/). *bioRxiv*. [Basic Science / Preclinical]
Castillo JJ (2026). [PMID: 42138287](https://pubmed.ncbi.nlm.nih.gov/42138287/). *Am J Hematol*. [Review / Meta-Analysis]
Hong Y (2026). [PMID: 41886495](https://pubmed.ncbi.nlm.nih.gov/41886495/). *PLoS Pathog*. [Basic Science / Preclinical]
AI-curated news mentioning primary effusion lymphoma
Updated Sep 3, 2026
A retrospective study highlights the clinicopathologic and molecular features of primary effusion lymphoma and fluid overload-associated large B-cell lymphoma. This research contributes to the understanding of these rare lymphomas, potentially guiding future therapeutic strategies.